Iradimed (NASDAQ:IRMD – Get Free Report) will be releasing its earnings data before the market opens on Thursday, August 1st. Analysts expect Iradimed to post earnings of $0.33 per share for the quarter.
Iradimed (NASDAQ:IRMD – Get Free Report) last posted its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.31 by $0.01. The company had revenue of $17.60 million during the quarter, compared to analyst estimates of $17.26 million. Iradimed had a return on equity of 24.63% and a net margin of 26.48%. On average, analysts expect Iradimed to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.
Iradimed Stock Up 0.6 %
Shares of Iradimed stock traded up $0.27 on Friday, reaching $47.52. The company’s stock had a trading volume of 12,878 shares, compared to its average volume of 50,616. The company has a market capitalization of $601.60 million, a price-to-earnings ratio of 33.70 and a beta of 0.83. The firm’s fifty day simple moving average is $43.85 and its two-hundred day simple moving average is $43.56. Iradimed has a 52 week low of $36.12 and a 52 week high of $50.85.
Iradimed Announces Dividend
Wall Street Analysts Forecast Growth
Several equities analysts recently weighed in on IRMD shares. Singular Research reiterated a “buy” rating on shares of Iradimed in a research report on Monday, April 1st. Roth Capital reiterated a “buy” rating on shares of Iradimed in a research report on Monday, April 22nd. Finally, Roth Mkm reiterated a “buy” rating and set a $65.00 target price on shares of Iradimed in a research report on Monday, April 22nd.
Check Out Our Latest Analysis on IRMD
About Iradimed
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.
Recommended Stories
- Five stocks we like better than Iradimed
- What Do S&P 500 Stocks Tell Investors About the Market?
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- Investing In Preferred Stock vs. Common Stock
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- Where Do I Find 52-Week Highs and Lows?
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.